Scott Sanders Md Pllc

CLIA Laboratory Citation Details

1
Total Citation
16
Total Deficiencyies
8
Unique D-Tags
CMS Certification Number 33D2076613
Address 301 North Main Street, Suite 3, New City, NY, 10956
City New City
State NY
Zip Code10956
Phone845 499-2017
Lab DirectorSCOTT SANDERS

Citation History (1 survey)

Survey - February 12, 2018

Survey Type: Standard

Survey Event ID: FZ6Z11

Deficiency Tags: D3011 D3011 D5417 D5477 D6076 D6084 D6093 D6094 D6094 D5417 D5421 D5421 D5477 D6076 D6084 D6093

Summary:

Summary Statement of Deficiencies D3011 FACILITIES CFR(s): 493.1101(d) Safety procedures must be established, accessible, and observed to ensure protection from physical, chemical, biochemical, and electrical hazards, and biohazardous materials. This STANDARD is not met as evidenced by: Based on a lack of procedures, surveyor observation and an interview with the Moh's processor, the laboratory failed to establish and have accessible a safety procedure to protect the laboratory staff from physical, chemical, biochemical, biohazard material and electrical hazards. Findings Include: It was confirmed with Moh's processor on February 12, 2018 at approximately 11:45 am that the medical assistants cups and glasses were in the laboratory where fungal culture and KOH slides are prepared and read. D5417 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(d) Reagents, solutions, culture media, control materials, calibration materials, and other supplies must not be used when they have exceeded their expiration date, have deteriorated, or are of substandard quality. This STANDARD is not met as evidenced by: Based on surveyor's observation of the reagents used for mycology and an interview with the MOH's processor, the laboratory failed to discontinue the use of expired mycology reagents. FINDINGS: It was confirmed with the Moh,s processor on February 12, 2018 at approximately 11:45 AM that the KOH reagents in use in the laboratory had expired on March 14, 2016 - Lot# 15169. Approximately 276 patient Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- specimens were tested and results released from February 10, 2016 through the date of this survey. D5421 ESTABLISHMENT AND VERIFICATION OF PERFORMANCE CFR(s): 493.1253(b)(1) Each laboratory that introduces an unmodified, FDA-cleared or approved test system must do the following before reporting patient test results: (1)(i) Demonstrate that it can obtain performance specifications comparable to those established by the manufacturer for the following performance characteristics: (1)(i)(A) Accuracy. (1)(i) (B) Precision. (1)(i)(C) Reportable range of test results for the test system. (1)(ii) Verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population. This STANDARD is not met as evidenced by: Based on a lack of records and an interview with the Moh's processor, the laboratory obtained and began testing on the new Leica cryostat instrument in September 2016 and failed to validate the instrument prior to patient testing. D5477 CONTROL PROCEDURES CFR(s): 493.1256(e)(4)(g) (e) For reagent, media, and supply checks, the laboratory must do the following: (e) (4) Before, or concurrent with the initial use-- (e)(4)(i) Check each batch of media for sterility if sterility is required for testing; (e)(4)(ii) Check each batch of media for its ability to support growth and, as appropriate, select or inhibit specific organisms or produce a biochemical response; and (e)(4)(iii) Document the physical characteristics of the media when compromised and report any deterioration in the media to the manufacturer. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on the surveyor's review of quality control (QC) records for dermatophyte media (DTM) used to perform fungal testing and an interview with the Moh's processor, the laboratory failed to perform the sterility check on DTM. Findings Include: It was confirmed with the Moh's tech on February 12, 2018, at approximately 12:00 PM, that the sterility check for each new batch (shipment) or lot number of DTM in use was not performed from March 31, 2016, through the date of the survey. Approximately 276 patients tests were performed and read during that time period. This is a repeat citation from the surveys of October 21, 2014, and March 31, 2016. D6076 LABORATORY DIRECTOR CFR(s): 493.1441 The laboratory must have a director who meets the qualification requirements of 493. 1443 of this subpart and provides overall management and direction in accordance with 493.1445 of this subpart. This CONDITION is not met as evidenced by: Based on the surveyor findings and confirmed in an interview with the Moh's processor, the laboratory director failed to provide overall management of the -- 2 of 3 -- laboratory. The laboratory director failed to ensure that the: 1.

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access